NYSE:NBY
NovaBay Pharmaceuticals, Inc.
A biopharmaceutical firm developing novel medicines for serious diseases with a focus on innovative therapeutic solutions.
Key Metrics
Investment Thesis
Bull Case
Investors may see value in NovaBay if its novel drug candidates successfully advance through clinical trials, potentially leading to blockbuster approvals and significant market share gains. The company's focus on serious diseases offers the potential for high-margin products once commercialized, providing a strong return on investment upon successful market entry.
Bear Case
The stock carries substantial risk due to persistent negative net income of $-7.2M and a total shareholders' equity deficit of $129k, suggesting financial instability. Without significant external funding or immediate product approvals, the company faces an existential threat given its limited cash on hand relative to ongoing development costs.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel medicines to treat serious diseases, with recent operations centered on specialized therapeutic areas. The company serves markets requiring innovative drug candidates, leveraging a pipeline of assets aimed at addressing unmet medical needs in oncology and other critical health sectors. Key products include early-stage clinical compounds designed to offer differentiated treatment options for patients facing limited therapy choices.
Analysis
Management Discussion
The company reported a revenue decline to $9.8M in 2024 compared to prior years, while narrowing its net loss to $-7.2M from $-9.6M the previous year. However, operating cash flow remained negative at $-5.2M, indicating continued burn rates that require careful capital management and potential fundraising events to sustain operations.
Industry Overview
The biopharmaceutical industry is characterized by high R&D spending, long development cycles, and a binary outcome where only a small percentage of drug candidates succeed in reaching the market. Companies like NovaBay operate in a competitive landscape dominated by large incumbents and venture capital-backed startups vying for breakthrough therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $14.4M | $14.7M | $9.8M |
| Cost of Revenue | $6.6M | $6.8M | $3.3M |
| Gross Profit | $7.8M | $7.9M | $6.5M |
| Operating Expenses | $22.2M | $15.5M | $12.3M |
| Operating Income | $-14.4M | $-7.6M | $-5.8M |
| R&D | $174.0K | $68.0K | $42.0K |
| G&A | $7.5M | $6.3M | $7.4M |
| Marketing | $7.8M | $6.5M | $4.0M |
| Stock-Based Comp | — | $291.0K | $148.0K |
| D&A | $120.0K | $51.0K | — |
| Depreciation | — | $51.0K | $40.0K |
| Amortization | $363.0K | $152.0K | $152.0K |
| Other OpEx | $6.7M | $2.6M | $865.0K |
| Non-Operating Income | $3.8M | $-2.0M | $-1.4M |
| Pre-Tax Income | $-10.6M | $-9.6M | $-7.2M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-10.6M | $-9.6M | $-7.2M |
| Discontinued Ops | $0 | $0 | $-124.0K |
| Net Income | $-10.6M | $-9.6M | $-7.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-10.6M | $-9.6M | $-7.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $11.3M | $7.2M | $1.9M |
| Cash & Equivalents | $5.4M | $3.1M | $430.0K |
| Accounts Receivable | — | $759.0K | — |
| Inventory | $3.4M | $2.9M | $765.0K |
| Prepaid Expenses | $560.0K | $388.0K | $303.0K |
| Other Current Assets | $2.0M | $0 | $437.0K |
| Long-Term Assets | $5.1M | $1.9M | $1.5M |
| PP&E (Net) | $119.0K | $87.0K | $53.0K |
| Intangibles | $2.3M | $0 | — |
| Goodwill | $348.0K | $0 | — |
| Operating Leases | $1.8M | $1.3M | $955.0K |
| Other LT Assets | $489.0K | $497.0K | $480.0K |
| Total Assets | $16.4M | $9.0M | $3.4M |
| Current Liabilities | $4.3M | $4.3M | $2.8M |
| Accounts Payable | $1.1M | $1.1M | $623.0K |
| Current Leases | $453.0K | $495.0K | $398.0K |
| Deferred Revenue | $4.0K | — | — |
| Other Current Liab | $-4.0K | $1.1M | $565.0K |
| Long-Term Liabilities | $1.6M | $1.4M | $709.0K |
| LT Operating Leases | $1.6M | $1.1M | $709.0K |
| Other LT Liab | $0 | $334.0K | $0 |
| Total Liabilities | $5.8M | $5.7M | $3.6M |
| Shareholders' Equity | $10.6M | $3.3M | $-129.0K |
| Paid-In Capital | $165.1M | $176.1M | $183.3M |
| Retained Earnings | $-158.2M | $-174.8M | $-183.5M |
| Total L&E | $16.4M | $9.0M | $3.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-10.6M | $-9.6M | $-7.2M |
| Non-Cash Adjustments | $1.4M | $9.0M | $2.6M |
| Working Capital Changes | $2.6M | $-3.5M | $-533.0K |
| Cash from Operations | $-6.7M | $-4.1M | $-5.2M |
| Capital Expenditures | $112.0K | $19.0K | $6.0K |
| Cash from Investing | $-112.0K | $-19.0K | $1.1M |
| Cash from Financing | $4.6M | $1.9M | $1.5M |
| FX Effect | $0 | $0 | $-80.0K |
| Net Change in Cash | $-2.1M | $-2.2M | $-2.7M |
| Beginning Cash | $8.0M | $5.8M | $3.4M |
| Ending Cash | $5.8M | $3.6M | $907.0K |
Frequently Asked Questions
How does NovaBay Pharmaceuticals, Inc. make money?
Drug discovery and development operations, clinical trial execution for oncology-focused candidates, and potential licensing or collaboration arrangements typical of the pharmaceutical sector.
What are the main risks for NBY?
Significant ongoing losses impacting cash reserves and the ability to fund future development without external capital, heavy reliance on successful clinical trial outcomes for future revenue generation, potential for regulatory delays or rejections of drug candidates, and intense competition from larger pharmaceutical companies with deeper resources.
What is NBY's competitive advantage?
Specialized expertise in identifying high-value disease targets, a proprietary pipeline of novel drug candidates not yet available in the market, and strategic partnerships that can provide additional funding and commercial reach.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.